(Press-News.org) New research to be presented at this year’s Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) and published in the journal Diagnostics shows that people with hepatitis B immunity induced by vaccination have a lower risk of developing diabetes of any kind. The study is by Dr Nhu-Quynh Phan, College of Medicine, Taipei Medical University, Taipei, Taiwan, and colleagues, under the supervision of Professor Chiehfeng Chen.
The liver plays an important role in glucose metabolism, specfically maintaining the balance of glucose levels (glucose homeostasis) and it is thought HBV infection may affect liver functions and disrupt these metabolic pathways, increase the risk of abnormal blood sugar profiles and eventually increase the risk of developing diabetes, Thus, HBV vaccination, which provides immunity against HIV infection, may reduce this risk. However the role of HBV immunity in diabetes prevention among individuals without HBV infection is underexplored. In this new study, the authors evaluated whether HBV immunity reduces diabetes risk in individuals without HBV infection.
This retrospective cohort study used deidentified electronic medical records from TriNetX (a global platform that provides access to data on diagnoses, procedures, medications, laboratory results, and genomic information for biomedical and clinical research. At the time of analysis, data were extracted from 131 healthcare organizations within the Global Network, which comprises multiple Local Networks: US, Europe, Middle East, and Africa [EMEA], APAC (Asia Pacific), and LATAM (Latin America).
This study included adults (≥18 years) with HbsAb blood serology results, a marker of hepatitis B immunity, excluding those with prior HBV infection. Participants were classified as HBV-immunised (HBsAb ≥10 mIU/mL) or HBV-unimmunised (HBsAb <10 mIU/mL). Because individuals with prior infection were excluded, HBsAb positivity was attributed to vaccination, whereas negativity indicated either non-vaccination or lack of immune response after vaccination. The study inlcuded 573,785 individuals in the HBV-immunised group (HBsAb ≥ 10 mIU/mL) and 318,684 individuals in the HBV-unimmunised group (HBsAb < 10 mIU/mL).
Diabetes was defined on the basis of a diabetes diagnosis, diabetes medication use, or glycated haemoglobin (HbA1c – a measure of blood sugar control) of 6.5% or higher. The data was adjusted for demographics and comorbidities.
The authors found that the HBV-immunised group had a 15% lower diabetes risk than the HBV-unimmunised group. A dose-response effect was observed, with higher diabetes protection at higher hepatitis B antibody (HBsAb) levels. HBsAb levels of 100 mIU/mL and above and 1000 mIU/mL and above were associated with 19% and 43% reductions in diabetes risk, respectively, compared with HBsAb lower than 10 mIU/mL.
The diabetes protective effect was also associated with age. Overall, immunised individuals aged 18 to 44 years, 45 to 64 years, and 65 years and older had 20%, 11%, and 12% lower diabetes risks, respectively, compared with unimmunised individuals.
The authors discuss other important findings from the study, namely the geographical variation in the association, saying “stratified analysis revealed significant geographical differences in the protective effects of HBV immunity against diabetes. Notably, the United States—despite its wealth and advanced healthcare system—showed the least benefit in diabetes prevention associated with HBV immunity.“ The authors say that other studies are needed to clarify possible reasons for this.
Regarding the effect of ageing, the authors comment: “The association between HBV immunity and reduced diabetes risk was stronger in younger individuals compared to middle-aged and older individuals. This finding may be attributed to the natural aging of the immune system, also known as immunosenescence, which leads to diminished vaccine-induced immune responses in older adults.“
On health behaviour, they observe: „From a behavioral perspective, individuals who complete vaccination schedules may be more health-conscious and more likely to engage in healthier behaviors, such as maintaining a better diet or exercising regularly. This raises the possibility that health behavior may act as a confounder in the observed association.“
The authors conclude: “The potential for the HBV vaccine to prevent both hepatitis B and diabetes suggests that the HBV vaccine is a unique dual-benefit intervention. Traditional diabetes prevention requires lifestyle changes, dietary adjustments, exercise, or medication, which require long-term commitment and can be costly. By contrast, the HBV vaccine is accessible and cost-effective, especially in regions with a high prevalence of both HBV and diabetes, such as the Asia-Pacific region and Africa. Further studies are needed to confirm these effects and investigate the underlying mechanisms. If validated, the HBV vaccine could become a key tool for the prevention of both infectious and chronic diseases.“
*Note this is an early release from the Annual Meeting of the European Association for the Study of Diabetes (EASD 2025, Vienna, 15-19 September). Please credit the meeting if using this material*
END
Study suggests link between hepatitis B immunity and lower risk of developing diabetes
2025-09-02
ELSE PRESS RELEASES FROM THIS DATE:
Researchers find Medicaid is crucial to access treatment for opioid addiction
2025-09-02
Medicaid plays a key role for giving people with opioid-use disorder access to treatment, according to a Rutgers Health study.
Progress in life-saving treatment for opioid-use disorder with the medication has stalled in the past several years, according to a Rutgers Health study. However, researchers added that while some states were able to achieve substantial improvement, others lost ground.
Specifically, states that have expanded access to Medicaid insurance coverage since 2018 saw increases in prescriptions for opioid-use disorder treatment, according to the study, while states that haven’t ...
New research shows changing winters will hit northern lakes the hardest
2025-09-02
Duluth, MN - In the world’s cold and snowy regions, shorter and warmer winters are one of the most conspicuous consequences of climate change. For freshwater lakes, this means later freezing, earlier thawing, and thinner ice. A new study, published in Ecology Letters, shows that the ecological impacts of these winter changes may be most dramatic in high-latitude lakes.
“The ecology of ice-covered lakes is a bit of a black box for lake scientists,” said Ted Ozersky, a University of Minnesota Duluth biologist who led the research. “For a long time, we assumed that nothing interesting happened under the ice, so few studies looked at what goes on in ...
Wildfire ‘char’ may help suppress methane
2025-09-02
It's hard to believe that there is anything positive that could come out of wildfires. They have devastated homes, taken lives, erased memories, leveled cities and destroyed our forests and wildlands. But a University of Delaware professor has found that there is something of value to be learned from what’s left behind in the remnants.
The charred debris left in the wake of wildfires, such as those currently burning in Colorado, Canada and Arizona’s Grand Canyon National Park, is known as wildfire char. UD’s Pei Chiu, professor of civil, construction ...
Flexible, skin-mounted haptic interface can seamlessly bridge virtual and real-world experiences
2025-09-02
Immersing oneself in the virtual and augmented reality world is not only awesome for entertainment, it helps industries like manufacturing and medicine operate more efficiently. Nevertheless, as fast as the technology brings you into the world, the weight and stiffness of its hardware can just as easily remind you that you aren’t really golfing on the PGA tour or preparing for a surgery.
Inspired by Softbotics, researchers in the Soft Machines Lab at Carnegie Mellon University are developing wearable electronics to augment our senses with ...
WiFi signals can measure heart rate—no wearables needed
2025-09-02
Heart rate is one of the most basic and important indicators of health, providing a snapshot into a person’s physical activity, stress and anxiety, hydration level, and more.
Traditionally, measuring heart rate requires some sort of wearable device, whether that be a smart watch or hospital-grade machinery. But new research from engineers at the University of California, Santa Cruz, shows how the signal from a household WiFi device can be used for this crucial health monitoring with state-of-the-art accuracy—without the need ...
Despite relaxed prescribing rules, opioid addiction treatment still hard to find at pharmacies
2025-09-02
Faced with a worsening drug crisis, policymakers in recent years have made it much easier for doctors to prescribe the highly effective opioid addiction treatment buprenorphine. However, many patients may still struggle to find pharmacies carrying the treatment, finds new research led by the USC Schaeffer Center for Health Policy & Economics.
Buprenorphine was available at just 39% of U.S. retail pharmacies in 2023, a modest increase from 33% in 2017, according to the study published Sept. 2 in Health Affairs. But disparities in who can access the treatment have persisted. Pharmacies in predominantly Black neighborhoods (18%) and ...
California program successfully scales emergency department addiction treatment statewide
2025-09-02
A comprehensive study shows that California's CA Bridge program has successfully implemented opioid use disorder treatment services across more than 80% of the state's emergency departments, reaching over 165,000 patients and providing nearly 45,000 instances of buprenorphine treatment from July 2022 through December 2023 alone. The initiative proves that emergency departments can serve as a critical entry point for addiction care when provided with proper funding, training, and patient navigation support.
Why it matters
The opioid crisis ...
Mitochondrial-targeting drug attacks cancer cells from within
2025-09-02
Researchers at MUSC Hollings Cancer Center have discovered a potentially powerful weapon in the fight against head and neck cancers. The new drug, still in preclinical studies, attacks cancer cells from within by damaging their mitochondria, the cells’ energy factories.
The study, published in Cancer Research, was led by Besim Ogretmen, Ph.D., associate director of Basic Science at Hollings and director of Hollings' Lipidomics Shared Resource.
The multidisciplinary research team aimed to suppress tumor growth ...
Researchers uncover relationship between gut fungi, human genetic variation and disease risk
2025-09-02
Clinicians’ ability to diagnose and treat chronic diseases is limited by scientific uncertainty around factors contributing to disease risk. A study published September 2nd in the open-access journal PLOS Biology by Drs. Emily Van Syoc, Emily Davenport, and Seth Bordenstein at The Pennsylvania State University, United States, uncovers evidence of the first ternary relationships between human genetic variation, variation in gut mycobiome, and risk of developing chronic disease.
Some gut fungi are implicated in intestinal diseases. However, ...
Fluorine “forever chemical” in medicines not leading to added drug reactions
2025-09-02
Medicines containing a type of PFAS or ‘forever chemical’ called fluorine are not leading to higher numbers of adverse drug reactions according to new data analysis.
In a new paper published in PLOS ONE today, researchers from the University of Birmingham studied data from the MHRA’s Yellow Card system on 13 drugs containing carbon-fluorine bonds as well as six drugs which were structurally similar but not containing this forever chemical.
Using five years of data from 2019-2024, the research team analysed the number of adverse drug reactions (ADRs) per 1 million medicines ...